-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BRxzRbID8ysyzCFimn0VgIiKBuJKyAD+1gLUnmTVN4hDiNbPM6/p8GIBEvjXuvk8
 Ke/eihCSHJyMpt0Cr35EMA==

<SEC-DOCUMENT>0001299933-09-003670.txt : 20090909
<SEC-HEADER>0001299933-09-003670.hdr.sgml : 20090909
<ACCEPTANCE-DATETIME>20090909115848
ACCESSION NUMBER:		0001299933-09-003670
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090909
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090909
DATE AS OF CHANGE:		20090909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		091059757

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_34261.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	September 9, 2009
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On September 9, 2009, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the commerical launch of Caldolor, our intravenous formulation of ibuprofen. A copy of the press release is furnished as Exhibit 99.1.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits<br><br>99.1  Press release dated September 9, 2009 announcing commercial launch of Caldolor
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	September 9, 2009
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ David L. Lowrance
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: David L. Lowrance
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated September 9, 2009 announcing commercial launch of Caldolor
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>Exhibit&nbsp;99.1</B><BR>
<B><I><img src="e27351-92521032086334087d_1.jpg"></I></B></FONT>



<P align="center" style="font-size: 12pt"><B>CUMBERLAND PHARMACEUTICALS LAUNCHES CALDOLOR</B><sup><B>&#174;</B></sup><BR>
<B>IN THE UNITED STATES FOR TREATMENT OF PAIN AND FEVER</B><BR>
<I>* First and only IV ibuprofen for pain and fever<BR>
* Caldolor offers increased pain control while reducing narcotic use<BR>
* Conference Call and webcast at 11:00&nbsp;a.m. ET today to discuss U.S. introduction of Caldolor</I>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, TN, September&nbsp;9, 2009 &#150; Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) </B>announced today
that it has successfully implemented the U.S. launch of Caldolor<sup>&#174;</sup>, an intravenous
formulation of ibuprofen, designed primarily for use in the hospital setting. Caldolor is the first
and only injectable product available in the United States for the treatment of pain and fever.
Cumberland received U.S. Food and Drug Administration marketing approval for Caldolor in June&nbsp;2009.
The product is now fully stocked at the wholesalers serving hospitals nationwide, and is available
in both 400mg and 800mg vials.


<P align="left" style="font-size: 12pt">&#147;We are pleased to introduce Caldolor ahead of schedule, offering a new level of patient care as
ibuprofen advances to IV,&#148; said A.J. Kazimi, Cumberland&#146;s Chief Executive Officer. &#147;We have worked
diligently over the past year to prepare for the introduction of Caldolor to physicians and
patients as the only injectable product available in the United States for reduction of fever, and
as an important alternative for single-agent and multi-modal pain management.&#148;


<P align="left" style="font-size: 12pt">In preparation for the product launch, Cumberland conducted comprehensive market research, prepared
a full package of educational materials, optimized hospital coverage and recently launched the
product website. Caldolor will be supported by 113 experienced sales professionals across the
country, comprised of Cumberland&#146;s recently expanded hospital sales force of 77 representatives and
managers as well as its field sales force of 36 representatives and managers. Cumberland has also
expanded its professional affairs group to handle medical inquiries about the product.


<P align="left" style="font-size: 12pt">&#147;The introduction of IV ibuprofen (Caldolor) should allow anesthesiologists to achieve improved
pain control with less opioid analgesic medication, thereby improving patient satisfaction,&#148; said
Dr.&nbsp;Paul F. White, Professor and holder of the McDermott Distinguished Chair of Anesthesiology &
Pain Management at the University of Texas Southwestern Medical Center at Dallas and visiting
scientist at Cedars Sinai Medical Center in Los Angeles. &#147;The use of IV ibuprofen can help reduce
opioid-related side effects, and Caldolor is the first IV analgesic with antipyretic and
anti-inflammatory properties.&#148;


<P align="left" style="font-size: 12pt">Until now, the only injectable drugs available to reduce pain were opioids, such as morphine and
meperdine, and the non-steroidal anti-inflammatory drug ketorolac. Opioids can cause sedation,
nausea, vomiting, cognitive impairment and respiratory depression, and ketorolac has been
associated with side effects such as increased risk of bleeding as well as gastrointestinal and
renal complications. Caldolor is the first new injectable product available in the United States
in 20&nbsp;years for IV pain treatment, and provides safe and effective relief from both pain and fever.
Caldolor also offers reliable IV delivery of ibuprofen, which has a long history of safe and
effective use as an oral formulation.


<P align="left" style="font-size: 12pt">&#147;We are greatly encouraged by the medical community&#146;s favorable early reception for Caldolor,
particularly the rate at which hospitals are adding the product to their formularies,&#148; Mr.&nbsp;Kazimi
added. &#147;Moreover, with the imminent onset of the flu season, we envision Caldolor as becoming an
important new treatment for high fever often seen in hospitalized flu patients.&#148;


<P align="left" style="font-size: 12pt">Hospitals and other healthcare institutions interested in obtaining product supplies should contact
their wholesalers. Medical inquiries should be directed to Cumberland&#146;s Professional Affairs group
at 877-484-2700. For more product information about Caldolor, please visit
<U>www.caldolor.com</U>.


<P align="left" style="font-size: 12pt">Caldolor is the third drug in Cumberland&#146;s portfolio and the second for which Cumberland has
completed development and secured FDA approval. The Company also markets Acetadote<sup>&#174;</sup>,
the first injectable drug to treat acetaminophen overdose, which is a leading cause of poisoning in
the United States, and Kristalose<sup><FONT style="font-family: Symbol">&#210;</FONT></sup>, a prescription laxative product designed to
enhance patient compliance and acceptance.


<P align="left" style="font-size: 12pt"><B>Conference Call and Webcast</B>


<P align="left" style="font-size: 12pt">A conference call and live webcast will be held on Wednesday, September&nbsp;9, 2009, at 11:00&nbsp;a.m.
Eastern Time to discuss the Company&#146;s detailed launch plans for Caldolor. To participate on the
call, please dial 888-634-7543 (for U.S. callers) or 719-457-2731 (for international callers). A
rebroadcast of the teleconference will be available for one week and can be accessed by dialing
888-203-1112 (for U.S. callers) or 719-457-0820 (for international callers). The passcode for the
rebroadcast is 5439189. The live webcast and rebroadcast can be accessed via Cumberland
Pharmaceuticals&#146; website at <U>http://investor.shareholder.com/cpix/events.cfm</U>.


<P align="left" style="font-size: 12pt"><B>About Cumberland Pharmaceuticals</B>


<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on
the acquisition, development and commercialization of branded prescription products. The Company&#146;s
primary target markets include hospital acute care and gastroenterology. Cumberland markets
Acetadote<sup>&#174;</sup> for the treatment of acetaminophen poisoning and Kristalose<sup>&#174;</sup>, a
prescription laxative. The Company also recently received FDA approval for Caldolor<sup>&#174;</sup>,
the first injectable treatment for pain and fever available in the United States, and has now
completed the commercial launch of that product. Cumberland is dedicated to providing innovative
products which improve quality of care for patients. The Company recently completed the initial
public offering of its common stock.


<P align="left" style="font-size: 12pt">For more information on Cumberland Pharmaceuticals, please visit <U>www.cumberlandpharma.com</U>.


<P align="left" style="font-size: 12pt"><B>About Caldolor</B>


<P align="left" style="font-size: 12pt">Caldolor is indicated for the management of mild to moderate pain and management of moderate to
severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the
first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with
known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic
type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the
peri-operative period in the setting of coronary artery bypass graft (CABG)&nbsp;surgery. Caldolor
should be used with caution in patients with prior history of ulcer disease or GI bleeding, in
patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart
failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be
monitored during treatment with Caldolor. For full prescribing information, visit
<U>www.caldolor.com</U>.


<P align="left" style="font-size: 12pt"><B>About Acetadote</B>


<P align="left" style="font-size: 12pt">Acetadote is used in the emergency department to prevent or lessen potential liver damage resulting
from an overdose of acetaminophen, a common ingredient in many over-the-counter painkillers. It is
the only approved injectable product in the United States for the treatment of acetaminophen
overdose, the leading cause of poisonings presenting in emergency departments in the
country<sup>1</sup>. Acetadote is contraindicated in patients with hypersensitivity or previous
anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious
anaphylactoid reactions, including death in a patient with asthma, have been reported in patients
administered acetylcysteine intravenously. Acetadote should be used with caution in patients with
asthma, or where there is a history of bronchospasm. The total volume administered should be
adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid
overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid
overload can occur, potentially resulting in hyponatremia, seizure, and death. For full
prescribing information, visit <U>www.acetadote.net</U>.


<P align="left" style="font-size: 12pt"><B>About Kristalose</B>


<P align="left" style="font-size: 12pt">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique,
proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient
age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.
Excessive dosage can lead to diarrhea with potential complications such as loss of fluids,
hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in
diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly,
debilitated patients who receive lactulose for more than six months should have serum electrolytes
(potassium, chloride, carbon dioxide) measured periodically. For full prescribing information,
visit <U>www.kristalose.com</U>.


<P align="left" style="font-size: 12pt"><B>Important Note Regarding Forward Looking Statements</B>


<P align="left" style="font-size: 12pt">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private
Securities Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E
of the Securities Exchange Act of 1934. These forward-looking statements reflect Cumberland&#146;s
current views with respect to future events, based on what it believes are reasonable assumptions.
No assurance can be given, however, that these events will occur. As with any business, all phases
of Cumberland&#146;s operations are subject to influences outside its control. Any one, or a
combination, of these risk factors could materially affect the results of the Cumberland&#146;s
operations. These factors include among other things, market conditions, the commercialization of
Caldolor, Cumberland&#146;s dependence on Acetadote and Kristalose to generate almost all of its
revenues, intense competition from existing and new products, which could diminish the commercial
potential of Cumberland&#146;s products, an inability of manufacturers to produce Cumberland&#146;s products
on a timely basis or a failure of manufacturers to comply with stringent regulations applicable to
pharmaceutical drug manufacturers, maintaining and building an effective sales and marketing
infrastructure, Cumberland&#146;s ability to identify and acquire rights to products, government
regulation, the possibility that Cumberland&#146;s marketing exclusivity and patent rights may provide
only limited protection from competition, and other factors discussed in our Registration Statement
declared effective by the SEC on August&nbsp;10, 2009. There can be no assurance that the results or
developments anticipated by the Company will be realized or, even if substantially realized, that
they will have the expected consequences to or effects on the Company or its business and
operations. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The Company does not undertake any obligation to release
publicly any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events.


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.


<P align="left" style="font-size: 12pt"><U>Investor Contact:</U>
<BR>
Angela Novak
<BR>
Corporate Relations


<P align="left" style="font-size: 12pt">615-255-0068


<P align="left" style="font-size: 12pt"><U>anovak@cumberlandpharma.com</U>


<P align="left" style="font-size: 12pt"><U>Media Contact:</U>
<BR>
Rebecca Kirkham
<BR>
Lovell Communications
<BR>
615-297-7766
<BR>
<U>Rebecca@lovell.com</U>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT style="font-size: 12pt"></FONT><FONT style="font-size: 10pt"><sup>1</sup></FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT style="font-size: 10pt">National Poison Data System, American
Association of Poison Control Centers</FONT></TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e27351-92521032086334087d_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e27351-92521032086334087d_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!=`9P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MHKQGQI\?OA5X$G>SUOQ5:S:A;W_]EZCINBVNJ>(M0T2^?P^WB>UA\26WA_3]
M4/A5-0T7R;K3[[Q4VB:9>M?Z5;V]])=:OID-W=.G4JRY*4)U)?RPBY/=+9)]
M6@NENTO5I?F>S5QE[\0/"FG^/O#GPPNM7MX?'/BSPGXS\=:!X?=+G[5J/A/X
M?:KX%T/Q?K4,BV[6@M]%UCXE^!K"XCEN8IY)?$$#6T4Z6]VT'XR?M(?\%I]`
M^%^C6[_#;X$^*==UN:#6HM03XC^)=`\)VVAW444T.BWD5IX0;XAKXGMI;U8[
MJ\T[^VO"LO\`9SHJZE%>O)!:_F5_P1S_`&P/CI^V?_P5]^*OQ'^.7B.SU34-
M)_8D^)6@^%?#FA:?_8W@_P`%>'F^//P&U+^Q/#.D-<7MTEL;R\FDFU'6M3UK
MQ%J"):Q:KK>H)8V0@^PP?!&;U,MS/.,;3AA,!E^`Q&*BY5:<Z^)JQCRTJ<*5
M-S<(*I*,ZDZDH>Y%QA&3FG'Q\;G%'"U\%AH)U*N+QM#"[-0IQG/WY.3WDHJ7
M*DFKV;=M_P"P.BD'0?0?RI:^,/8"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`KA/B7\3/`_P?\$Z]\1/B-XCT[PKX0\-VBW>
MJZQJ<DJPH9KF"QL;&TM[:&YO=3UG6-2N[/1_#^A:7:WFL^(==O\`3M"T6QO]
M6U&RLY^[K^5C]OC]I/X@_MF_M=7G[,OP8\*:YXO\&?`+Q?J&B)IOA32/&&KZ
MGXE^)NFRVO@KQYXO\0Z7<Z'IT.A:%\/-<U'4/A_I>O-8W/AZPTR3Q)XX/CFZ
M\)>.K6+1O>X>R.IGF-E1=58;!X6D\5C\7)QC"AAH2C%I3G:FJU64E3HJ;MS-
MS<7"G.W+BL2L/"+LY5*DE"G!)MRENW9)OEC%.4O1)-.2:_1&^_;/\6?M`>)[
M.V\&MK7@#X9P_P!DSVNG)/\`V7XZUG5-.UJ+6FO/$6OZ#JLZ66D2'3M'L3X1
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MME]W7K<_CL_:\^]>_6;_`-"K<_X-Q?\`E)U\7O\`LSCXD?\`JZ_V?*_JG\8?
M\$P?V(/B`_F^,/@U=ZO,3F1XOBI\9M'65L`%I+?0OB'IELS.!^\`A".6?Y`K
ME:_/C]LS]C+]G']@CX<:/\<?V/O`-]\!OBYXD\;:7\--<^('@WX@?$IO$FJ>
M`]6T'Q)XHU/PO=WFM>+]5#Z7?^(?!OA;5;J,)YD]UHEBTDC+&4;['$>(.3U.
M&\SR:&%S-XG&X&IAJ=25'"QHPJ2Y+.<EC)3Y/=WC!O5Z::^'BLDQ-?&X#$QJ
MT8PPF.I8JI%N?-*$'[T86A9RLW:[2;5FU>Z_H`'0?0?RI:_CRLO^"D?[:WA*
MSALM,^.>KWEK!*CLOB/PUX'\5W-PB2LS0W&J>)/#&IZNZ2@LLCKJ"3\AXYDD
M1'7ZT^%O_!=;QWHNJ6]E\>/@_P"'/$FA2WVGV\^O?"Z\OO#.N:5IB1R+J=_+
MX=\37OB'3?%.J2/Y,UK9V^O^![$-YL3S+'(C0?D!],?TLT5\Q?LX_MA?`']J
MC18=1^$GC>UO]973EU+5_`NL1OHOCKP_"L>F->-J7AV\VSW=CIMUJ]CI=WXC
MT&76O",FK2MIVG^(;ZXCD5?IV@`HHKX$_P""G/[:%U^P!^Q?\6_VGM*\(:?X
M]\1^"T\*:3X3\):MJ]SH>F:OXD\:>-/#O@VPDU"_M-.U*X-CH46NW7B>^T^&
M.SGUFQT.ZT6VU?1;K4(-6L^K!8/$YCC,+@,'3]KBL;B*.%P].ZCSUJ]2-.G'
MFDU&*<I*\IN,(K6<HQ3DN?%8JC@L-B,9B9JGA\+1JXBM-IODI48.I.5HIRDU
M&+M&*<I/2*;:1]]T5_('\,O^"G__``<@?&/X>^#?BI\-/^"=G[,'B[X?_$#P
M[I?BSP=XFM/#GBVUM=<\/:U:QWNF:G;V^H_M>65_##=VTL<L:7EI;W"J0)8D
M;(KH?$7_``42_P"#F'POH&M^)M>_X)L_LR:5H?A[2M0US6=3ET#Q))'I^DZ5
M:37^HWLD<7[84TKI;6EO+*ZQ122E5/EQR/A3]I+P\S6-:5"6;<*QK1JNC*D^
M),L52-6,U3E3=-UN=3C.\7#EYN96M=I'S:XQP$H1JPRWB*=*4%4C5CD&9NG*
MG*,9*I&:P_*X.+YE).S6M[-'];=%?DG_`,$9O^"COB7_`(*:?LH:M\9_'G@3
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M"A2O2DHRB_:5(QFI6<-;['[ZT4#D`^M?GA_P58_:S^(W[#?[!OQT_:C^$VC>
M"O$/C_X8#X9'0=&^(FFZYJW@Z]_X33XS?#GX=:J-8L/#?B+PGK<_V?1?%^I7
M>G_8?$&G^7JD%E-=?:[..>RN?'P.#KYCC<'E^%498G'8K#X+#QG)0C*OBJT*
M%&,IO2$74J13D](IMO1'IXO$TL%A<3C,0W&AA*%;$UI).3C2H4Y5:CC%:RDH
M1;45K)V74_0^BOSQ_P""4W[6/Q'_`&X_V"/@/^U)\6M'\%Z!\0?B@/B>-?TC
MX>:;KFD>#[3_`(0KXR_$3X>:6=(T[Q'XC\6:Q;FXT7PGIMUJ'VO7[\2ZI/?3
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M*#J?&WC/PS\.O!_BKQ_XUUO3?#/@WP1X=UKQ;XM\2:U=I8:/X?\`#7AS3KC5
M]=UO5;V0&.TT[2M+M+J_OKF3Y(+6WED;A37A2HUH5GAY4JD:\:CHRH2A)5HU
M5+D=)TVE-5%/W'!QYE+W;7T/8C4ISIJM&I"5&5-58U5*+INDX\ZJ*=^5P</>
M4KV<=;V.HHK^67_@F5_P7H^-'_!0W_@HWXG_`&>+3X9?##P=^S/<>'_BMXJ^
M'5_+H/BJ+XWRZ#X1ELD\)R^,]87XCZQX$BU35+.X^WZ_I>A^%3:Z9<7`TFPU
MK4DL#K&I?T'_`+7_`,6?$GP#_9/_`&F_CKX.L]%U'Q;\%_V?OC'\5_#&G>)+
M:]O?#NH>(?AW\//$/B[1K'7K33=0TC4;G1KO4-'M[;5(-/U73+^6QEN$L]1L
M;DQW,?MYKPSF^39IA,FS"C3I9AC:6"JTJ*K0FHK'3=.C&I./NPFIIQJ1;M%K
M>VIY67Y[EV9X#$YE@ZDZF$PT\3"=1TY1<OJJ;G*G&23E"25Z<M.96;Y;GT71
M7\8G[,W_``61_P""_O[8WP^O_BG^S5^PK^R5\4_`.E^*=1\$W_B+2]"\7Z/;
MVWBC2M,T;6+_`$EK7Q3^UUH>HO+;Z;X@TBZ:>.S>T=;U$BN))8YXXOH"Z_;K
M_P"#GRSMKB[G_P""97[,!BMH9)Y%@T_5+RX9(U+LL%I9_MFSW5U,P&V*VMH9
M;B>0K%#%)(RH??K>'>;X:M/#XC-.%\/B*4^2K0K\19;2K4Y^[>%2E4JQJ0FK
MZQE%25M4>32XSR[$4X5J&7\05J-6*G3K4LAS*I2J0E:TX5(4)0G%IW4HR<6M
MGJC^KNBOP+_X(@?\%<_BG_P4LL_C]X*^/GPM\%_#7XO_``&O?!D]]+X"C\4Z
M/X?\0Z-XRG\8V$MF?!_BV^\3:WX8UGP=J7A!;366O_&>J'5Y=?M_LNF:.=)O
M([CV#_@N!_P4+^-/_!-;]E7X=_'3X%^&OAAXJ\5^*_V@_#'PGU+3/BQHOBK7
M?#L7A[7?AQ\5?&%S?65KX0\:>!=3BUN'4_`FDP6UQ/J]S8+8W6I12Z;-<2VM
MU9^)/A7.:7$<>%:U&G3S>=>C0C3E6@Z$I8BC&O1G'$1YJ<J=2E.,XR3TORS4
M9*27I1XARR>1RX@A4J3RZ-&I6E-4JBJI4JLJ%6#HSC":G"M&5-II*\>9-Q:D
M_P!E**_D/\`_\%+_`/@Y+^*'@7P7\2_`7_!.+]F'Q)X&^(?A/P[XY\&>(K7P
M]XJ@M=?\*>+-(M->\.ZU;0WW[7]K>Q6^J:/?V=]`EW:V]RL5PJSP12!D'6_\
M-Z_\'.__`$C)_9H_\$?B#_Z,:O8EX?YE"4H3SGA.,X2<)QEQ-E2E&<6HRC).
MO=2C*Z:>J:L]6<$>+\%)1E'*^))1DHRC*/#^:-.,E%IIK#V::E=-:-6:W1_6
M'17SW^REXN^./CS]G7X0^,/VE?!6C?#GX\^(?!MAJ7Q2\#>'H)K71/"_BR62
M=;_2=+@N/$/BR=+2W5(C%YGB36BRN'%_,&!'\MFI_P#!;'_@L%\4OVW/VL_V
M1_V-_P!E;]EGXTS_`+.GQ8^-GARSM-2\-^.['Q0WPY^&'Q;O?AIIWB3Q#J6K
M_M+>"?#U[JMQ))H2:H-%L;&.:_OY)[+1K2Q5H[;R,GX6S'.Z^9T<'6RZ$<I3
MEC<5BL?0PV"A#V[PZJ1Q55QHRI2J+W*G,H2BXR3M)'=F'$."RRGE\\12QTIY
MGIA,/0P5>OBI25&->4)8:G%UHSA3;<X.'-%QDI)69_8O17\I9_;C_P"#H`<G
M_@F9^RT!QR8+SN<#_F]+UKUG_@C_`/\`!9C]J;]LO]KGXT?L9?MB?`GX;_";
MXG_#3P9XM\51S_#_`$WQMX1N-#UKX?\`B[PMX.\4^`/%OA#QCXE^(-Q<:I+<
M>*7U6S\06?B?1;&Q@T&YT]M(U=]9L]0LO0Q7`F<8?`8W,*6+R/,:.7THXC&0
MRS.\!CJ]##N48.M.C0JRFH1E))Z7>O*G9HY:'%N6U<5A<'5P^;8*KCJKHX5X
M_*<=@Z5:LH.?LH5:]&$7/E3=E?;6R:/Z6Z*_/'_@JM^UE\1OV'/V"_CK^U)\
M)M&\%^(/'_PO7X8G0=&^(>FZYJW@Z]_X3;XS?#GX=:I_;%AX;\1^$M;G^S:)
MXOU*ZT_[#XAT_P`O5(;*:Y^UVD<]C<K_`,$I_P!K'XC?MQ_L$_`?]J7XM:-X
M*\/_`!`^*'_"T!K^D?#S3M<TGP?:?\(3\9_B+\.]+.D:=XD\1^+-9M_M&B^$
MM-NK_P"UZ_?^;JD]]/;?9+26"QMOG_['QW]B_P!O\E/^S?[4>3>T]I'VOUY8
M18YP]C\7LUAY)^U;2YGRI-WMZ_\`:>$_M5Y,I3^O+`?VFX<C]FL)]8^JJ?M/
MAYW7]WV:N^7WGH?H;1117EGH!161K^O:+X6T35_$OB35=.T'P[X?TR_UK7M=
MUB]M]-TC1='TNUEO=3U75=1O)(;/3]-TZR@GO+Z_O)H;2SM89;FYFB@BDD7^
M/KX,_P#!S#\3O&?[:/@C2_B)\+?AAX)_X)V?%+X__$#X*>!OC7?:%XG\/?$"
MVM-$L]`BT3Q3XR\9^*/B98_#?2+?PU-\1?A1XR^,-F?"ML?`7@'QBTXO-5N[
M"TO-;]_)>&<XX@I9C6RO#*O#+,.\1B.:K"E*?N3J1H8>,VGB,34A2JRIT:=Y
MR5.5M58\?-,]RS)ZF"I8^O[*>/KJA12C*=KRIPE5JN*:I4(3JT83JS:BI58)
MO5M?V.445X/^U+\3-?\`@M^S/^T+\8_"=KI%[XI^$_P0^*_Q*\-V?B"VN[S0
MKO7O`W@/7O$^D6NM6FGW^E7]SI-Q?Z7;PZE;V.J:;>36;S1VM_9SM'<1^)2I
MSK5:=&"O.K4A3@F[)SG)1BFWHKMK5['JU)QI4YU)7Y81E.5M7:*N[+O9'O%%
M?RR?\$A/^#BW3?VROBG+^SI^V5H?PV^#/QC\;:W;6GP+\7>`K?7]!^%'CV]N
MX;.VM_A;JD'C'Q7XRU7PU\3M3U`S3^#+N[\22^'OB%+=Q^#-.M]!\;6_AC3/
MB1_4W7JY[P_FO#>/GEV;X9X?$1C&I!J2J4*]*6U7#UH^Y6IWO%R@WRSC*$K3
MBTO/RC.,OSS!PQV75U6HR;C)-.-6E4C\5.M2E:=*:TDHR2YH.,XWA*+917\\
M?_!0O_@K!^T;^RC_`,%5OV)_V'/ASX0^"^K_``F_:4;]FY/&_B'QGX;\;:E\
M1-&'Q>_:,\7_``D\4MX2U?1?B)X>\-63VOAG0[2\T,ZUX2U]+/6WGNKY-3L7
M338_Z'*RQ^48W+<-E>+Q481I9OA)8W!N%13E*C&K.BW-+X)<\'[KUMKLR\'F
M>%QV(S##8>4G5RS$QPN*4H2BHUI4H5DH-JTX^SG'WH];KI=E%?R<?MH?\%F/
M^"FGP]_X*=_%K_@GW^QC^SU^SA\:;[PM;^"KWP)I7C#POX]G\?:W:ZO\!_!?
MQB\5/J>L6OQW^'WA.8:,==UPVIM]+TIO['L;6"1+W4%DN+JMJ7_!0/\`X.<M
M-L+O4)_^"9/[.IM[*"2YG73O"GB[5KYHH1O=;73-,_:[OM1OYBH(2VL;.YN9
M6(2&)W*BOIH>'^<.A@J]?'\/8+^T,'A,?AJ..SW`83$2PN-IPJ8>HZ%>I"HE
M.,[7LXJ<9PYFXNWB/C'+/:XFG3PF=8E83%8C!UZV$R;'XG#QQ&%G[.O35:C1
MG3DX3WL[V<962DC^M"BOY,OV9O\`@Y!^)?@SXR>$?V?O^"JO[).M?LD>)_%Z
M6]S;?$V'P[\0/AQH>CVNO:O#HOA;5/%?P@^+UI<>+-%\`3W5GXE_M;XGZ?\`
M$'Q#;65QI]M%_P`(F=+36M>TC^D/]H7XV:S\)],^&FE>!O".G^/_`(F?&OXF
M:=\*?A=X8UGQ+-X+\-W^O_\`",^*_B/XJU/Q%XMB\.^*GT32?"/PE^'7Q)\=
MNL6@W][XAG\*V_A+1HCK?B'3"/%S7AC.LEQ.&PN/PL(O&TY5\'B*.(P^(P6*
MH4[NI7HXVC4GAW2HQ7/7<YPEAZ=IUXTXM,]/+L^RO-</7Q&#Q$I_59QI8JA4
MHUJ.+PU:7PT:V%K0A7C4F[QIKD:K235)S>A]%45^6'[!7[?/BW]J;7KKP[XC
M\&0WNB:A:?$#4/!OQ>\,Z;X,\/>$M>F^&"?!NX\9Z"^A^!_CW^T]X3NH;./X
M]^!=+T#Q?X3^.GBR76/&_A3X\>`O'W@/X,^(OA%IMO\`$C]3Z\O'8#$Y=B)8
M;%04*L5?W9*<91YI133B]'>,E*,K3A).,XIH]#"XJCC*4:U%MPE;XHRBUS1C
M-)II:N,HRNKQ::<9---\1\3+OQS8?#KQU??#'1-&\2_$BQ\(>([WX?\`AWQ%
MJ;:)X?USQM::3=W'A72-<UA(+I])T?4==CL;34M3CMKB6PLY9KJ."9XEC;PC
M]CW]CSX1?L7_``DT/X9_#'0],&JIH^BVWCWX@+I,-CXF^)6OZ5%=M)K_`(BN
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MJD&FP^#/']G-J,VGZ+9WMW'8PW=_96TUV\(MXI[RVB>17GB5OTUHH`_B"\0_
MLP_M+6UK)=7'[._QU@M45Y'N9OA%\0(H$C3<[NTS^'EC5%4$LQ8*`&R?E./C
M7Q39W>GWMUI]_:W-C?VDKQW=C>02VUY:2*(]T=U;3*D]O(/.BS',B.-Z_+S7
M^B/56]L;/4K2YT_4;6WOK&\ADMKNSNX8[BUNK>52LD-Q;RJ\4T4BDJT<BLK#
MJ*`/X2/V?]2U/1M1T75M%U/4M%U;3IX;O3M6T?4+S2M4T^[B;=%=6&HZ?/;W
MEE=1'F*YMIXIHF^:-U/-?UC_`+'/[5^H_&"QM/!?Q!CMD\<V^G>;8:[8VT%E
M9^*ELH&DO!<:=;[(;+7Q;0RZG<1Z=;PZ1=PI?2V=II*6L=E+W_B_]@[]DKQ?
M!`H^!_@?P=>V<&H1:?J?PVTF'X<W-I/J**LE_-;>#1HVDZW>6LBBXL?^$FTW
M6[2VN#(WV22*YO(;CYB\1?L0ZY\(OMOB+X<ZYJ_C?PMI$8U6/1Y!<V?Q0TK^
MS!X?:WET.Y\+VUG%XIU>&[7Q'XCBN]`A\'^(M.73]!T7PMH7B7Q%,NH.`?JQ
M7\]O_!SG_P`HK?&?_98O@]_ZD%Q7[H_"OQ?<>._A_P"&?%-ZD2WVI6!^W/;V
M]O:6-W>6L\MG/J>EVEOK?B+[+HNL-!_:^A6]UK-YJ<6BWVGKJPMM3^UVL'XC
M_P#!R_H.HZQ_P2A^*VH64:O:^%?B/\&-?UAV+#R=/N/B%H_A:%TPC*7;5O$N
MEQ;7>,;)'8,S*$;ZO@62CQEPPY-)?VWET;MVUEB81BO64FDEU;21\[Q;&4N&
M,_44V_[)QKLM[*A-OY))M^5S[O\`^"37_*,W]A3_`+-?^#__`*AVF5]V^*/#
M6B^,_#>O^$/$EF=1\.^*=%U7P[KVG"YN[+[?HVMV,^FZG9?:]/GM;^V^U6=S
M-"9[.ZM[F(/YD$T4JHZ_S3?\$]?^"Z/_``2T^!?[#?[)_P`'?BC^TY-X9^(W
MPT^`_P`-_!GC;P]_PI/]H36O[%\2Z#X:L+'5M,.K>'?A3J^A:B;2ZBDA-YI&
MJ:AITY0O:7EQ"5E;Z.^)W_!Q'_P2HD^&_P`0%^'?[7$A^(!\%>*3X%#?`']H
MI1_PF2Z'?MX7(;6_@N=&5AKBV.QM7']EJ^TZ@RVGFL/2SGA'BNOQ!F=7#\.Y
M]R5<WQCHXB.4YA[-*6,FH5E5CA](1;4_:Q=HQ7M(MI)G-E_$G#E/*L#&IGF3
M<U/+<*JE&69X'GYH86GSTW3E73YTURN$DGS>ZU<_3O\`9)_8C_9B_87\%^)/
MAY^RS\,A\+?!WBWQ.?&7B#1QXS^(7C8:AXE;2M/T1M3.H?$7Q7XNU2U)TO2M
M/M?LEE>VU@!;B7[+Y\DLLG\RG_!;/_E.S_P1P_[*%^R]_P"M?VU?H[_P;O\`
M[8_[4O[</[)WQB^+G[5/Q,7XH^*-!_:)U?X=>&M8'A'P!X+?3]"T;X9_#/Q+
M-IATGX>>%/"6E3QK?^,);J/4+NQN+Z9[F:V>Z\FTABC_`#._X.!M;TGX*_\`
M!6;_`()+?M(_$J\;P[\'?!WB[X7ZUXE\5KI^JZM_9FE_!G]I#PKX\^(MV-*T
M6PU#5M2_L#PKXIT75&L=&LM1U>]6Y^S6&FW-X]K;W7O\,8#,,N\0\SRO,\:L
MSS6&69]AJN)IXC$XV>,Q,LEK34:=7$PABJ]11:A:=-3O!I*R1X7$&+P.+X(P
MN-P&'6!R^KB,HK4:$J='#PP]%YKA?BA1E*A1@G>3<9^S2?,W;4_LK'0?0?RK
M\4?^#B3_`)0]_M=_[GP$_P#6I/@=2#_@XF_X(\#C_AKF;CC_`)-__:>_^<Q7
MY??\%F?^"S?_``3:_:Q_X)N_M&?`+X`_M%OX[^+7CP?"(>%/"C_!_P"._A8:
MK_PC'QZ^%GC773_;OC+X8>'_``W8BP\->&M8U$C4=8LS=?919V0N;^XMK6;P
M^%^%.*,-Q-PYB,1PYGM##T,^R:M7K5<IQ].E1HTLQPM2I5J3EAU&%.G!.<YR
M:C&*;;23/5X@XAR"OD.=4:.>9/6K5LIS"G2I4LSP4ZE6I4PE6,*=.$:[E.<Y
M2C&,8IRE)I)-M'ZB_P#!NW_RAU_9`_[K_P#^M0_&NOR)_P""RW@#PG\6?^"]
MG_!.3X5>/M+;7/`?Q/\`@IX0^'/CC0UO]1TLZWX,\<_$KX\>%O%6C'4M(N[#
M5;!-6T'5=0T^2[TV^L[ZW2Y:2UN8)U21?U^_X-Y;2[L?^"/?['T%[:W-G*\'
MQUNXXKN":VEDL[_]ICXRWVGWBQ3(CFVO["YMKZRG`,5W97,%U;O)!-'(WY9_
M\%4/^5B__@E+_P!B7\(__5U?&BO:RNI*GXA\;5:4W&<:7'LZ=2G*SB_8YE*$
MX3CLU=2C*+NG9IIH\K,8)\$<*4ZD4TY\&0G":337M,OC.$XO3O&46NZ:W15_
MX)N?%7XF?\$;?^"@?B3_`())?M-^)-8UO]FOX\^(_P#A+OV)/B5?7&FZGIEC
MJOC;6;^U\,Z=<RI!INHZ)'\3;^TE\$^+?#-E:R:=X<^/>CQZCX;\.OX5^)NL
M_$;4/6?^"UGQO^*_[<?[1_PK_P"")O[(]U=OX@^(%]X3^('[8WCBWT?3[_2?
MAE\,+271O&&B:=K-Y=ZI8R6UAH6EOIGQ7\86!.A7OB2Y?X-^`O"/B34M6\=Z
M[X4N/U&_X*^_\$U/#'_!2G]ES5/`5@N@Z#\?/AW+>^-/V??B!JUA'(='\6B"
MV75_!&K:K%Y>JZ=X&^)^GZ?:Z!XH-G-/:Z9JEGX3\=W6@^)K[P)I.BW7B?\`
MP11_X)B^*?V(OAAXU^-?[3;VWB[]NC]I;7-1\7_&GQCJ6K1^,O$7@[1M3U*;
M6+;X:MXY&IZO::_K&H:U/=>./BGXCT&Y6P\5^-M1L]-GU+QCI7P^\(>*KS%9
M[D-6G#CBM*B^+,-26$J9/[.*I8W/E&,<)Q,XQ:C]7IX=5,3BZ,8P3S2E0490
MC7YI]#RC-H3J<*4U57#M:;Q$,R4FZN&RAROB<A<I*[K3KRC0P]5RDXY;6K/W
MIT%"'XZ_L)_`?X>?LP?\'+7Q-_9]^%&FMI?P_P#A+^RWX,\&^'HYX=,CU/48
MM-_90_9Y^W^(_$$FC:;H^FW_`(K\5:M)J'B?Q=K%KI=@NN>)]8U;6)+6&:^D
M6OZ=_P#@I;_RCF_;Y_[,O_:@_P#5)>-Z_GM^#7_*V5^T_P#]D-T3_P!97_9Z
MK^A+_@I;_P`HYOV^?^S+_P!J#_U27C>CBBK4K\4<!UZTY5:U?AS@>M6JS;E.
MI5JJ-2I4G)ZRG.<I2DWJVVQ9!3A2R/BJE3A&%.GG'$L*<(I1C"$*]>,81BM(
MQC%)12T222T/XN?^"+__``51_:5_8F_92\6?"7X0?\$U/C;^V!X8UGXY>+?'
MMU\3_AUK7CO3]"TO6-7\%_#K0KGP7-;^&?@#\3[`ZEI=KX8LM7GFE\1V]T]O
MK]HKZ3;11Q75[^L>I_\`!Q-^VOH>FW^M:W_P0Z_:=TC1M)L[G4M6U74_&7Q5
ML--TW3K*%[F\O[^_NOV/H[:RLK2VBEN+JZN)(X+>"-Y972-&8?('_!OI_P`%
M7/V!?V'_`-BCQU\(_P!J'X\GX8?$'6?VC_&_C[3?#W_"K?C1XU^T>%-8^'WP
MIT/3]5_M7X=_#KQ;H<7VC5/#6M6QL9]3BU.'[&)KBRBM[FTFN/W/?_@XD_X(
M[JN4_:]+ME1M_P"&?_VHUX+`,<GX(X^526QWQ@<FOIN*\'"?$N<2EX49CG//
MCZLGFE*MQ5"./4G%_6(?5&\+%5%;^"O8I-M+E=CY[(,14ADN5I>(V!RQ0P6'
MBLOK4<@=7!\M."^KSEB)QKN5)KD;JQ51O65V[GY7_P#!JQX+7Q7+^W-^U5J7
MCWX=7_B;XM>-_!VEZI\*_"6MWLOB_P"'\_\`;7Q*\7:EJWC7POJNF+=Z-X;\
M6W/B"TB^&.L6FOZY::W%X;\;6-U<C5?#][!;>]_\'97_`"CM^"O_`&>E\/?_
M`%1O[15?$/\`P;*^)V^)O[>O_!2KXJ?#O1]1\._!+Q@/^$IL?#;B"TM?#S^/
M/C!XV\1_"C2-2TVRFN;&#5-,\'P>-].L5@GN+>TAM]8@L[B6&0M)]O?\'97_
M`"CM^"O_`&>E\/?_`%1O[15<^+IU*7C5EBJ2O*6*R6:I6C&6$IO*<.J6#J**
M2<\-!*GSM<U1152?O29TT90EX6XWDA:,*&94_:7;CB91S.MSXN+;=HXB;E5Y
M4W&$I.$7RQBSXD_95_X.#OVC/@I^R_\`LX?!O0/^"3/QF^(VB?"?X#_"+X:Z
M/\0=*^)/CJRTSQUIG@;P!X>\,V7C+3;&U_9A\06MGI_BBVTR+7+.TM]?UR"V
MMKZ*&'6-3C1;V?\`I%_X)D_MR>/OV_?@7XP^,'Q$_9G\5_LK:SX9^+6M_#:U
M^'OC#Q#JOB34]6TS2/!O@3Q/%XPAO-9^'7PSO+>RU"[\87NC167]A7D23Z!<
MW":O,;EK+3_S&_8:_P""[?\`P2H^#O[%?[(?PD^(W[4W_"._$'X7?LQ?`?X>
M>.M`'P/_`&CM8_L3QCX,^%OA3P[XETC^U=!^$&J:)J?]FZSIM[9?VAH^IZCI
M=[Y'VC3[ZZM)(IW^IO\`B(C_`.".O_1WY_\`$?OVI/\`YR5>#Q)E&)QSQE++
M/"_.LMQ;QU2:S2BN(\=[:FJL^=QP^(H2PZCB4XS4H?`FE3;B]?7R/,J&$6%J
M8_C_`"G'8=82G'ZA/^PL)[.;I4U%.O0JJOS4/A:D[S?QZZ'[5U_GY?L7_MY_
ML]?\$^/^"V__``5)^+7[1^K>)M(\'^+/BE^U[\/-&G\+>&+[Q5?2>)+[]K6R
M\2P13V-@Z2V]I_9GAG4V>[8F-9EAB(S**_NG_9\_:"^$7[4_PA\'?'GX$>+?
M^$Z^$_C^'5[CPCXK_L'Q-X9_M:+0?$.K^%=6;^P_&.B^'O$EA]DU[0M4L-NI
MZ/9O/]E^U6RS64UM<S?QH?\`!*SX%_!+X^_\%Y?^"KWA;X[?!WX6?&KPQI'C
M']L3Q#I/ASXM?#[PE\1M"TOQ!#^V+H&EPZYIVD^,-(UBPL=8BTW5-2T^/4K6
M"*]2QU"^M%G%O=W$<F?`\,/A,LX_IYQA,:Z%#*,-3QV#HR6#QT90S&,)4E+$
M4JBH5J=5)3C5I-QY90<5+:^+)5Z^:<%SRZOAE6JX_&5,)7K1EB,+)3RV4X3:
MHU(.I"<'>#A4BGS1ES<MS]A3_P`'.'_!*U4ROC7XQR$`85?@YXA!;V!>=%'_
M``)A7Y&_\$4/C#I7[6O_``7J_;._:@^'&@>([+X:>-OA3\7?$^G3^(;."TU'
M3M&U?Q]\)-&\-)KB6-Q?Z?8:SK,6GR7D>D0ZC>R1)#J"PW%]%IEW=C[S_P""
MQ_\`P0H^&_Q+^'VC_M(?L"?!;X6?"S]H'X%VD.MR?!SP%\+?`FF?#+XY>%_#
MU]+X@_L*\^$]OX;F\!^(/B)8W;3SZ0FJ>&-0LOB/I3W7PZ\;6/B"QF\(_P#"
M-_0'_!"3_@I#^RM^U!\)KKX&>$/A!\'_`-D_]ISP5]JUCXK?`7X7^!?#OPM\
M)>.-0M1!I6K?%?X?^'M#TO28+ZVO!9V5OXJT6[6\\4^";Z.'2=5GU'15T#Q!
MJWJTWP[@N#\[S7A'+LUQ=3,L!4R7.Z>.S'#UJV0TJU>E6AB:V%H8*E*OAJ_L
M(NCBZ=3V*FG3K>RE&<'Q3_MG%<1Y9E_$>-P&%IX+&1S+*IX7`UH4\XG3I2I.
MC2Q%7%5(TJ]'VLW5PU2"J\O+.G[6,XM>Q_\`!Q%_RAX_:^_W?@#_`.M2?!"E
M_P"#=S_E#K^R!]?V@?\`UJ3XVTG_``<1?\H>/VOO]WX`_P#K4GP0K\O/^",W
M_!9W_@FW^R=_P39_9P^`'Q__`&BG\"?%KP%_PN`^+/"J?"'X[>*ETK_A*OCU
M\4?&NA#^W?!OPQ\0>'+[[;X:\2:-J/\`Q+M7N_LWVLVEW]GO[>ZM8/*P&69E
MFOA;*AEF7XW,:\/$"I5G1P.%KXNK"DN',/3=2<*$*DHP4ZD(.;2CS3BKW:.S
M%8_`Y?X@NMC\;A,#2J<'0I0JXS$T<-3G5EG4IJG&=:<(RFX4YR44V^6,G:R/
MZ[Z*_$__`(B)_P#@CQ_T=Q-_XC_^T]_\YBOT;^%?[7W[._QJ_9JB_:_^''Q)
MT[5_V<I?#7CWQB?B?J^E>)/!6CVGACX8:MXET3QYKNJ:?XYT3PWXBT;3/#>H
M>#_$BWMUJ^BV2/:Z7+J-K]HTZ:VNYOAL;P_GN6PI5,QR7-L!3KUHX>C/&9?B
M\-"K7FG*%&G*M1@IU913DJ<6YN,92M:,FOKL+G.48Z<Z>"S7+L9.G3=6I#"8
MW#8B5.E%I.I.-&K-P@G**YY)1YI15[R2?XB_\'&7[9GBSP/\$?AY_P`$_?V?
MVN-:_:6_;L\1Z;\.X_#WA_5+"+Q':_";5=<T_P`.7^DE8O%&DZGH=Y\;/%^H
MZ5\+=!EUS1-2\'>+_""?&;29K[3]3T.*6+7_`&N/^"*/A34?^"+WA?\`8M^%
MNEV6O?'#]FKPO%\7/AWXBT^U=+SXB_'RQAU36_BA;P->7EM>+:?&9M=\8^&_
M#.C:OK*:/X9N]2\`-?R2:;X#TV.#\7OV>/V5/VG?^"_7[7_[3W_!0WPK^TIX
MY_9`\&_"_P"(NB?#S]G#QKI?AWQ!K_BCP_H>D:3?/HG@3PL=$^,?ABZ\!>)/
M"G@;4?#OC'XFW?AKQ$^@:M\0?BOKFK>'K2*#6]2%M^I?_#BG_@I1_P!)_?VQ
M/_,[?_1@U^K3H97PQAN'LF_UOR_(\WR7&PSS.\/7P&;8F=;.ZT*,J5"K5P>#
MJ4)8?`X":P7LZ=>:DZ^,E-1E4LOSR-7,,]KYSF+X;QF;Y9FF'EE>4UX8W+,-
M&GE-.<HSK4Z6+Q,*JJXO&7Q2JSI1O&EAG!RC",I?7W_!`#_@H,_[<W[$6@Z#
MXXUN?5OCY^S6FA?"CXJW6HW=_J&L^+-%73[D_"[XI:EJ&JZMKFKZM?>./#.D
MW6G>*-?UF_2_\0?$CPAX\U<6-CI][IT)_17_`(*!?\F(?MJ?]FG?M%?^J@\8
M5_&%9_#?XL?\&XW_``5%^`?C[XG_`!HU/XY?L_\`[4WAS7M#^,GQ<U#PS>^'
M)_$&AZUXMT^'XHZEJVB2ZM\8/%FI^+/@MK^J_#KXR7NIZ5)+XB\>:=JDO@K2
M]1M9?$_B,)_9M^WS<07?[!'[9MU:RQSV\_[)7[0\L$T+!XI8G^#_`(P9)(G4
ME7C=2&1U)5E(*D@@U\QQ=E&!P/$N69MDLZ=;A[B+$4<RRJO0C4CAX3^MQIX[
M!056%.I!X7%*3A2J4X3AAZM"#7/&=OH.'<RQ>+R3&9?FD)T<XR6F\#F%*K*,
MZLH^PYL'BIRA*<)?6<.ES3C4G&=6G5E&3BXG\4O_``2Z_P""0GPV_P""G?\`
MP2<^+VJ:1<Z+\._VJ_AC^UK\3;3X-?%JZM)5TW5+)_@U^SWJA^%WQ6;3K>?4
MM7^'.I:A<:A=Z1J=O::EXA^%_B/5;[Q=X2L=4L=2\<>!?B#^NG_!'_\`X+!_
M$_PY\4)/^"7/_!4B/6OAS^UE\.]:M?AS\,/B;\1KJW74/B;?^3"WAKX7?$W7
MX[B[TO5OB?K&DW.E7OPC^+%GJFI>'OVC_#VJ:"HUS5?B7JWAOQ%\<>E_X--?
M^4=WQK_[/1^(/_JCOV=Z^Y_^"P/_``1]^%O_``4[^%T6K:5+H7PZ_:N^'FBW
M=I\(OB_=VEPNFZUIPEN+_P#X5+\6_P"RX;C4M8^&6KW]U?7.F:G;6>I>(_A;
MXBU.^\6^$+34].U;Q_X"^(_T?$>>Y?B^)^(>%^*7.632S;$/*\TA'GQG#F*J
MNE>K1N^>O@*TO][P5^62_>4TJL8M_/Y!E>-P_#^2Y_D"@LR6748X_+YR<,+G
M>'IW4:52VE+&THZ87%;W2I5FZ;O#\1O^"TW_`"L0_P#!*'_KK^PY_P"MN_$B
MO[5:_P`QG0?BY^UY\0?^"L__``39^&W[<^GZ_:_M&?LM?M%_LE_LY:]?^,K=
M?^$[U[PCX<_:3TGQSX*UCQSX@AU/5=/^(6NSZ;\0IX=+^*NDW-Q8?$_P/!X/
M\;3ZQXQUK6=8\>^*O].:O&\1<OJ95@>"LOJ5J&(EALBKP6(PU15</7IO,*TZ
M5>A46DZ5:E*%6G+1\LU=)GK<$XR&88WBS&4Z=:C'$9OAYNCB(.G7H5%EV'C5
MH5H/X:E&K&=*5KQ;AS1;BTW_`!B>$_\`E;R\7?\`8L6O_KN_PI7]G=?PG_&7
M]I7X*?LB_P#!TG\4?CS^T)XS/@#X5>$M"\+V7B#Q0/#GBOQ6;"X\3?L%>!?#
M>BQC0_!6A^(_$5U]LUK5+"RW6>D7$=L+@W-V]O:Q2S)_0!_Q$3_\$><@#]KE
M\9`8M\`?VH!@%@"1M^"C[L`EB#M^53@EB%/3QOP_GV9RX2Q66Y+FV889<"\-
M4GB,%EV+Q5%58X:3E3=2A1J0]I%3BY0OS)2BVDI*^'"N<Y/@(\04<=FN6X.L
M^*L]FJ.*QV%P];DEBDHS]E5JPGR2::C+EY6TTF[.WD'_``<P_`SX;?$?_@F%
M\2/BQXHT&"Y^('[.WBOX:>,/A=XFAALDU71KKQ_\5OAY\)O&&BR:C)9S:D?"
M_B'PUXPDO=7T"SO;*PU/Q)X:\%ZUJ,=U<^&=,$7J/_!)C3IOVRO^".W[$VH?
M$75+SPQXV\%>%M3T#X8_$OX>K9Z3XW^%NK_L_P#Q!^(7P.^&GCOP9?ZU:>(=
M.7Q5#\/?"5MH/C*SU_2]=\%?$SP_K_CCP%\1O"/BKX8^._%_@?6OP<_X*U?\
M%@(?^"K=EX6_X)K_`/!-KX<?%;XH3?%7XFZ';^)/%$N@:3H$/QBT_P`(W:^)
M]%T+P?X>\1H?$?A_P%IVO:7I/Q+\7_$3Q_)\*)/!NE>`);WQ59V/@H>(]4MO
MZY?V"/V8-._8Q_8[_9\_9EL18O=_"KX>Z?IOBN]TJ^U/4=(UCXC:Y=WOBSXH
M^(=&N-86+45T7Q)\1]?\5:_H]I/;60T_3=2M=/AT_3H+6*QM^?.</C.'^`LC
MRO-E+"9Y/B7%9UE^"K-+&X#*98"&&E[6B[U,+#$XU2K*A5455;E-P<XU%'IR
MRKA\YXNS7,,N<<3D\<AH97C,52_W7%YDL;*M'V556CB)4,(_9RJTY/V:E%*5
MG!O-^!7[$O@/X'_%/Q#\93X[^(WQ*\>ZSH4WAK3-0\;_`/"OM'TSPCHVI^&/
M@]X0\50Z!X>^%?@#X;Z'=7GC30_V?/@E#X@U/Q38^)+^TE^'6F#PC/X6LM6\
M36.M_9U%%?FN)Q5?%U/:XBK*K44(4TY62C"FN6$(1BE"$4M;1BKR<IRO*4F_
MN*-&E0AR48*$7)R=KMRD[)RE*3<I.R2O)MV26R05^0/[7'ASQ?\``CQ__P`+
M*\&^*=5T6'QMKU[?Z'J.EOXBM;O3-5,ND^*M?\):QKM]JFI6NN67B36],U#Q
M-;>%6EL=!OO#6GS>'/\`A$+G0O!EU=77Z_5RWC7P5X7^(OA;6?!?C/1K/7_#
M6OV@L]4TR]$H26-9X;J">VN+>6"]T[4K"\MK;4-(UC3;FSU;1M5M+/5=*O;/
M4;.VN8L#4_!.P_X*X_%[X7Q26?Q!\`^%_BM96FG306U[9:A)\/?%5UJ8NWEB
MOM5U.STOQ#X7FMDM&6S^Q:;X)TER4CNVNY7$L,_M_A3_`(+F_LL:S-IUAXD\
M!?&OPGJ$Y@AU.Z.A>$==\-Z7<%$^U.NH:?XSC\07^GP2F417$/A*.^N(424Z
M7!+(;>+Y-_;;_P"";'Q;\"V]YXH^#EEK7Q?\$+;QR7%C8VD5W\2-(N)KZ"P%
MO/X;TFW1_%5N_P!JL[K^U/"^GK/$/[8GU+PYHFD:3%J-[_/U;_\`(1GR"#Y\
MN0P*D<MU#`$'ZB@#^U2T_P""J7["%VJ%/C?,C,N2C_"_XPL4;GY28O`$B<*I
M9FWX"X(S\VWV?X*?MG?LV_M$^*;WP7\'?B'<>+_$FG:%<^)KVP;P-\1?#D<&
MB6=YI>GW-Z=1\5^$M#TQS%>ZUIEN;6.\>\+W/RV[+#<-%_$?HO5/\_Q"OVU_
MX(Q_\G*^/?\`LA7B;_U8/PPH`_I=HHHH`***^(/VL_\`@H!^SU^R-X=U6Y\9
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MI.N:'JUO=Z;JNFW<1:*ZL;ZVGMIXR4EC920?CW_@GIKWQ-^)'P`_X:#^+3ZI
M8>*OVG/&.L_&ZP\%7.K1ZMH/PY\`:KIVB>#OA3X7\$O!-);VWAK4_A?X+\(>
M/;I%AL+K4?&'C3Q7X@U73;#6=:U&TA^XIW,<1<=5:/TY!D4$<@]02,XR,\8.
M#3Q5">`Q=7#^U3K82M[*52C/W8XBDU&I[*I%^]&G64HPJQ=JBBJD;*22F$HU
MZ,9R@N2K#FY)I2O":NE.+5KN+7-%J\7>+U1^8NL_\$6O^"5^O:K?ZQ>_L0?`
M^&\U*YEN[F+2-%U+0-,269MS)8Z)H.K:;HNEVRGB*RTRPM+.!<)#!&@"U4M/
M^")W_!*JRNK>[@_8D^#9FMIHYXA/:>(;N`O$X=5GM;KQ!-:W4+%=LMM<PS6\
M\9:*>*2)V0^&?"O_`(*A?M4_$K]AZS_X*(Q_L6?!M?V=;7P;XM^)_BGPYH/[
M9/B74?CMI7PR^''B;7=%^).NZ1X,\1_LC>#_`(<:_P"(/#6B^%?$GBO2_"L_
MQCT%?$]EI\&E6FN6>MW]MI[_`+%?#CQ]X;^*OP]\"_$_P=<SWGA+XB^#_#7C
MKPO=W5G=Z==77AWQ;HUGKVBW%SI]_#;WUA<3:=?V\D]C>V\%Y:2LUO=0Q3QO
M&OT..QW&.67^MYUFU/V>*K8&;HY[5Q"I8O#)>VP]1X;&U/958)_#4Y>=*7)S
M*,FO%PF&X=QR3PV6X"7-1I8B/M,IA0<Z%=7I58>WPM-SA-1^*',EHI6;2=;X
M:?"OX9_!CPAIOP^^$/P]\$_"WP%HSWTFC^"?AWX6T3P9X2TJ74]0NM6U273O
M#OAVRT_2+*;4]5OKW5-1EMK2*2^U*\NKZ[::ZN)I7Y/XW_LY?`3]I;PU:^#_
M`-H'X-_#3XS>&M/N+J]TO2?B3X,T'Q?!HFI7EC/ID^K^'WUJRNY_#^M&PN;B
MUCUK19;'58(I6%O>1'FJFO?&.71/VDOA3\`/[`%S'\3?@S\?OBY_PE/]J>2=
M%_X4=XR_9L\(?\(^=$_LV;^TO^$G/[0O]HC51J^G_P!B#PC]C.F:O_;_`-JT
M7#^+_P`?G^%?QI_9-^$@\*_VXG[3OQ(^)'P]?7?[<&F?\(6?`/P%^)WQN36/
M[,_L;43XC_M/_A6Y\,_V>-1T#[%_;0UDWUY_9O\`9-_XE*&9>WHXJC4Q$<5B
M*.)S"CBH8IPQ,J=!8EXG$*NJL:L)Q6&Q-[SC5GR-04N>'-Z-2I@'1JX>K&C+
M#TJN&P-6A*AS454Q/U98>@Z7LW"4)_6<.M(NE%3]]Q49\OQY_P`.1/\`@E+_
M`-&2?"#_`+X\4?\`S25M^'O^",?_``2S\,:M::UIO[#WP'N+RR<R01:_X:N/
M%6E,Q1XR+O0O%&H:QH=_'M=OW5]IUQ&&VN%#JK#].*^&OVX?VQ]3_94\,>`=
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M_M'?$3X/>$O%GQP^$<&GVOPX^)&IQ7YU_P`)P:3JFI:WID>FF"^ALB+'5M8U
M.^@^U6EP5GO)2#MVJ.U_9_\`CG\//VF?@I\,OC[\*-7CUOX>_%CP?H_C/PS>
M">QENX+35;</<:/K,6GWE_;Z=XE\/7ZW>@>*=$:[EN]`\1Z9JFB:@(K_`$^Y
MAC]:N&9(7*-M;Y55L`[2S*H;#`@XSG!'.,<=:\=5,7@L164:F(PN)C]8PN(Y
M:E2E67-ST<50JM.,VI^_3K4YMJ7O1FF>@XX;$4:<G&C7H-4ZU)\L*E)J/+4H
MU::LX>[:,Z4XJ\6HR@T[,FHK\9/#'_!1O]K?6/V,M&_;\O\`]C+X(S?L^/\`
M"JV^._B;0?"7[9?BO5?CCH_PBLX!K/C76-*\&>+?V0/`?P[U_P`6>#_"%MK/
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MGA_PYH>E`Q6$<GV;3H,N9#)(_M/COP-X3^)W@GQA\./'FAV?B;P/X_\`"^O^
M"_&/AO41*=/\0>%O%&E76B>(-$OA#)#,;/5-*O;JRN1%+'(89W$<B/AQ\"_M
MO_\`!0NT_8C^+'[-_A?Q3\+;OQ;\*_BY#X^USXP?%>U\;:3X=C_9Y\`^"_'/
MP#^&0^(^K^%M3T:XD\;^%8/&/[0WA&7QFVF>(=$U/P;X2T_6_%D=AXBM-/N[
M2U]\_;'_`&H-,_9,^#$_Q%'A>3XB^//$OB[P9\*/@I\(K'Q/X=\(Z]\9/C=\
M3O$%GX5^&_PUT+6?$\\.G6+ZQK-]_:/B35Q!J<_A3P)H_BWQJVC:M:>&;JRE
MZ)8+.<1_8U>?UBM_:$?J^3U98I3]W`UWA50ISE5MA%A*J5J=1T51I2IUTHT:
MD)O!8G*Z:S*C'V,%A&JN8TE0E%)XFC&LJDX>S2Q#Q%/>=-5?;5(SI-RK0J07
MRK_PY$_X)2_]&2?"#_OCQ1_\TE2P_P#!$K_@E1;RQSQ_L2?!TO$ZR();?Q)-
M&61@P$D,WB%X94)&&CE1XW7*NC*2#]F_LH_')OVFOV9_@-^T._AD>"V^-GPH
M\#?$\^$1K/\`PD0\-?\`":^'K#7QH?\`;W]DZ%_;/]F"^%G_`&G_`&+I7VWR
MOM']GVGF>0GNFI:C8:/I][JNJWMKIVF:;:7%_J&H7T\=K9V-C:0O<7=Y=W,I
M6*WMK:".2:>>5ECAA1Y)&5%8CIKY[Q3A<15PU;/,[AB*%6="K".;8V;C5IR<
M)P4J>)E&34DXWA*2E]EM,BEE>1UJ5.M3RO+)4JM.G5IR_L_#1YJ=2,9PE:5%
M2C>+B[22DMFD[H\X^$7P,^"WP`\-WG@[X%?"/X9_!CPCJ&L7'B*_\+?"GP)X
M7^'OAV^\0W=G8:==Z]>:+X3TO2=-N=9NM/TK2["YU2>V>^GL=,TZTEN'M[&U
MCAY3]HW]EG]GW]KGP3I7PX_:1^%OAOXN>!]$\4V?C72O#GBA;]K"Q\5:?I.M
M:%9:W!_9][8SK>V^D>(]<T^-FF:/[/J=TK1L7!7Y3_8E_P""BFE?M<^.?&/@
M;5_A7XC^#]SJ'A*/X[?LV7WBO51,_P"TG^R7J_CKQ/\`#_PI\??#_AZ_\/>%
MO%/@IM3U/PYIVM:UX&\2Z-/=:#X3^)'PC\00>(=;MO'4*V'Z5UPXN&:Y5F4I
M8FIB<+FE*<:SKQQ+>)C4G%352.*HU9-U/>M.4:KG"HITZCC4A.*Z,-+`8[!J
M.'A1K8&<725%T%&BX1=O9_5ZD(I4[6<(NFH2@XRA>$HM_E9_PY$_X)2_]&2_
M"#_OWXH_^:2C_AR)_P`$I?\`HR7X0?\`?'BC_P":2O<OC7^UOXL\.?'/1?V6
M/V=?@O/\>?C_`'7@:U^*WC5=>\9R_"?X'_!;X9:AK=]X?\.Z[\7_`(O+X,^(
M6HZ?X@^(6L:+XDTWX<_#WX?_``\^(OCC74\,^(/$&LZ1X6\'::WB=]GX:_$O
M]M1/B9X6\'_'/]EOX3:5\/\`Q3I7BR>[^+WP&_::NOB?8_#[7=!M]-O=!TKX
M@^`_BI\$OV?/%#:/XTBN-5TO1/$/PTD^)E_8Z]IUG%XI\*^'/#^I2^)--]?^
MT>+(T%B*F?YE1C*B\1"G7X@G0Q%2@DY1J0P]7&PK-58IRH1Y.?$QM+#QJJ4'
M+@^J9`ZKI1RG!SE&I[*<Z>31G2A5O%.$JT,(Z2Y'959<SA1<6JTJ;1[S\&O@
MQ\+_`-GOX;>&?@_\&/!FD?#WX9^#8M1@\+^#M"6X72=%BU?6=2\0ZDEHMW<7
M5P%O-:U?4=0E\R>0^?=RE2J%47RGX5_L3_LK_!+XR?$?]H3X4_!7PAX)^,_Q
M=F\2W'Q*^(6CKJ8USQ?-XP\30^,O$TFJ&YU&XL]VL^*+>#6KS[-:09O(U,?E
MQDQGZEK\JO@Y^VO^UO\`M(^+/VG=,^!7[+G[.UYX2_9H_:E^*7[+&I>(?BW^
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M>_%SPKX*\%?$&5M3&O\`AKX>>/M;^)_@_31%K&H0Z.='\<>(_AO\(]9UO[;H
M,>EZC?\`VWX>^'CINIWE[I$`U6UL(-;U+R+]H?\`:#D^!7B3]F'0$\*?\),O
M[1G[1^E?L_O=?VX-%;P>-4^$WQ>^*(\6K"=%U@:^;?\`X52=".A&31O-&O\`
M]I_VS$=+%AJ.6#EF-&O6H8#$5J5:I1KTZ_U3%^SA7H4J<JV(A*K2JQIUZ')2
ME/E<I0JJ*Y%)RBGIBOJ;HTZ^,I4YTZ52C4INOA_:2I59RC"C.$)TY5*57FJ1
MBI*,9PYG=Q7-;T#XV_`[X3_M'_#/Q'\&_C?X(T?XC?##Q?\`V.?$O@S7OM9T
MG6#X?U_2O%.BFZ%C=6=R3IWB#0])U6W\NX3%S90[MT>]&^`_^'(G_!*7_HR3
MX0?]\>*/_FCKZV_:E_:'E_9P\-_"7Q%%X4'B[_A9W[2?[/'[/;V9UP:"-&7X
M]_%7PU\,_P#A+OM!T76SJ!\*#7SK0T$0V`US[+_9QUC2//%_!].UMAL?G>6X
M2G/!YAF&!P>)K5^2.$Q]>A3JUZ,:$:\G2H5HVG&,Z,7.<%SKE49247RQ6PN6
M8W$2CB,'@\5B*%.GS/$82E6G"G4E.5-*I5I2O%RC-J,9/E=VTN;7\K/^'(G_
M``2E_P"C)?A!_P!\>*/_`)I*^O-._8[_`&:='_9RD_9&TCX2^'M*_9OET_5=
M)E^$NFW.M6/AN32]>\5WGC?7--D>UU6+59-/UKQ-J%_J.KV3ZB;;4UOKVPOH
MI],N[BSD^<OVI?VH_P!LG]FO0M;\?Q?LR_LT^-_AA#\3_A;\-_#.J3_MA?$_
MPQX]U9_C/\8O!/P7\#:MKO@N+]B3Q#X>\/B#Q#X_T34?%-EI_P`0/$W]D:+:
MZK+I=YXBOX+2QO\`ZQ^#&N_M):VWB9OV@_A=\%/AJEO_`&-_PAZ_![X]>./C
M>-9,HU/_`(2`^(/^$S_9N_9\;PP-/\K1?[)%@?&#:TU]JINSH":59C6>O%XC
MB*K@\-CL9F]?$X:->-7"^USZ.*K4\515&:G2PKQ=2O3Q&'6(I.4U3A4HJ;NT
MN8Y<-3R:.)K87"X"A1K^QY:ZAE4J$98>JYQ4:E;ZK"E.C5=":493<*W(^536
M^E\"O@!\&OV9OAWIGPF^`WP\\._##X=:/>:KJ&G>%?#-M-!80WVMZC<ZMJM[
M+)=3W5[=W=Y?74LDEQ>74\JQ""UC9+2UMH(O8:^8OVT/VBV_9'_97^.7[2J>
M$/\`A/F^#/@34?&__"&?V^/"W_"1C39K9#I?_"1'0_$HT?[0)B/MO]@ZKY6.
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M,=&U&PU9D\?ZOX.^,O[-_P"S]HOC#PAHFJ6VD6WBN'PIX_\`^$]MM/U674O"
M?P_\9W6GMHESW1H9I4P6%;Q*IX*+JXO`T<3F5##1;4I0JXG!X:OB:;M.=.=-
M5Z5-*O6I3I4I5*U*4(\TJV!CB*]J7-7:IX?%5:.$JU7KR.G1Q%>C1G%\L9PF
MX5)OV5&<:DU"E44G[3^SE^RS^S[^R-X(U3X<?LW?"SPU\(_`^M>*;WQKJOAS
MPLE\MC?>*M1TG1-"O=;G.H7M_<->7&D>&]#L'(F$8@TVW58U(8M[_0*^*/VU
M_P!KC5OV7O"WP_TCX8_"B7]HK]I#XV^,W\$?`C]G72OB!X<^'.N?$:^T+1K[
MQK\0]:E\4>([+5[/PYX3^'GP[T/7?$GB'Q+=:+?:7;:D?#'AJ^N-+NO%VF7\
M?)3AC<UQJBISQ>-Q4Y2E5Q-=<TVHN=2MB,5B9J$*=.G&52M7KU(TZ5*$JE6<
M81E);SEA<OPSERPP^&H12C"C2?+!.2C"G2H48.4I2G)0ITJ4)3G.484X.32?
M=_%;]C+]EKXX_%CX8?';XK_`WP!XU^,GP9O]&U+X9_$O4]):+QEX6N?#?B&'
MQ;X;2WUNPGL[R_LO#OB>%]>T'3=7DU#3M&U2]U:\TRUM9M:U=[[Z<KQ?]G7X
M]?#S]J'X'?"_]H'X4ZE_:?@+XK^$-*\7:$TESI=QJ6E->QF+5O"WB)-&U'5M
M.T[QAX-UR#4_"7C70X=2O)/#WBW1-9T*ZF:[TZ<+[),Q6-W!(*`/QC)"D,5^
M96`W@%2=I(!R.0*C$SQ:<<'BYXB^!E4PL,/7G4?U5JK+VM&%.;:I?OG-SC%1
M3FW)ZMLJC'#\KKX>%)1Q*A6E5I0BO;IP7)4E**7M'[/E492NU!1BO=22^`/C
M/_P2M_X)\?M#_$OQ+\8OC7^RS\-_B)\3O&+:2WB;QEKRZ^=6UEM"T+2_#&D&
M[-GKEK;$V.@:+I6EP^5!'_HUC"'WR;G;SS3O^"*?_!*W2[ZUU&U_8B^"KW%G
M/'<0I?:;K>J6;/&=P6ZTW4]<N].OH&^[+:WUK<6LZ$QS0NC,I^KOV-OVAV_:
MS_9:^!G[2;>$?^$";XS_``_T?QT?!O\`;X\4_P#".?VL)6_LO_A(1HGAL:Q]
MG$>/MO\`86E^;G/V2/'/TQ7JU<WXDRVK4RZ><9OAIX"<L'+#4\TQ7L\/+"OV
M+HP5'$.CR4G3Y(^S;IVBN1N-F<-/+LFQE.GBXY=E]:.*A#$QK3P-#GJQKQC5
MC4DZE%5.:I%QE+VEIW;YU>Z/$/@[^S-^SG^SQ_;8^`7P$^#/P0'B?^S_`/A)
MA\(?AAX)^&J^)#I(NUTEO$*^#=$T8:V^EKJ&H#37U3[6U@+^^^R&'[9<^;[?
M7YTZI^U1^TE\1?C[\>?@M^S%\"/@CXKTS]FC6OAQX4^)7C+XY_M,:O\`"F]U
MKQG\0OAQH?Q7CT?P/X$^'7P&^//B,>&-)\'^+O",<WQ!\;-X2L]8\37?B30?
M"GAWQ%#X1U;5U^W?AEK?CCQ)\//!6O\`Q,\#V?PS^(6M>%]$U3QI\/-/\66O
MCNS\$^)+^P@N=7\+0>-+'3-&L?%*Z'>R3:<VNV.EV5EJ3V[75I"+>2,GBQV&
MQM/EQ..JQJ5L1"A6E[3&4*^+<,30C7P\ZM-5ZF)2GAY0G>I!<BE"$^64HQ?1
MA,1A)\U#"0E&E0=2FG##U*6&O1JNC5C2J>SC2DX5E*,E%MR:E./-%2D=S111
M7G':%%%%`!7RY\;OV+/V7OVB+J75?BM\'/"FN^)9I8)YO&>GQ7OA;QM=2VFG
M?V38_P!I>+O"EYHGB#6[;3[`1P6.F:YJ&I:3;BWM<6#+;1*OU'10!^(?C#_@
MA]\'9TMV^&?QH^(_A*X$TTEY_P`)MH_AOX@V;Q/('A@T^WT6+X;75F(!NB\R
M\U#57ECV%L2J\DORE^T+)<?\$%/!_AO]K-47]JI?BIXQM/V:)?`1<?`UM!;Q
M=HFN_%)/&?\`PD^SXQC5!8?\*<?13X=7P_I_VLZ^-1_MZU&E_8=1_IIK^9O_
M`(.I/^3"?@)_V>U\/?\`U1'[1]?2\'9?A,UXGR7+L?2]O@\9C84<11]I5I>T
MIRC)N/M*,Z=6.J6L)QEYGC<0XO$8')<PQ>%J>RQ%"BITJG)"?++VD(WY*D9P
MEHVK2BUY7.?\"_\`!Q'X@^)MI''H?[*FF^%K^\5?)N]3^,LWB>U@D)4[FLK;
MX6^%Y9X\%E,?VVW?JPF'RY^[/@)^W3\?_B^;NS\3CX;:+%J96'2[WP5X0UK3
MM7T:.4*%E:?Q3XS\::1J5Y&=S+)-H4%H2WSV#!<'^,?]F#_F%?\`;.OZ<?V,
MYP]Y;0VEMJ6K7UE:6FJW&D:!I.J>(]?72Y=0MM+&J1^'M!M-1URXTR._NH(+
MK4+?3Y;2SWF6[FAACDD7]/XPX5X?R>A6>7971H2BFXN4J^)DFF]8_6:E9W=N
MG338Y,FQN*Q=*$\16=24HW;Y803=H6TIQBEJ^B2UU/JO]IKQS\3K"RM].N?B
MM\0]1DT6TUFR>_BUY/";:]#JT#6UV/%&B_#RS\&^$M?"VL@M[2*_\.20603[
M3:Q17TMQ=R_FA^RE^PQ/^U[\:X+'6]`N+7]GCX;7]F/BAJ%G-=^'-.OQ#807
MNB_"GPS?:4;.\.MZY9R:?+K4?AR[TZY\$>"+E=8N=5T'5M<^'UOXC_=?4/V2
M]5^,?B(ZG\1WE\(>#;?5(K@:#87UG>^*?%$>E>(]4CN+'5+JR>\TKPYX9\1:
M;I.BW<-SI&IWWBZ\\/\`B;4+,GX;>+=(M[Y/NGPEX0\+^`O#VG>$_!F@Z7X:
M\-Z2MP-/T;1[2*RL;=KV[N-1OIQ#"JA[K4-1N[O4=1O)3)=:AJ-W=7][-/=W
M,\TGP6'XI>497/"Y;RK'8BFX3Q$%RPPJDG%RI\J2E646W3</<IRES-N4>5^M
M/"*M4O57[M--Q>\I1Y;*W\FCYKV;M9*SN;EM;6]G;PVEI!%;6UO&D-O;P(L<
M,$,8"QQ0QH`D<4:@)'&BJB(`JJ%``9>G%M(3G@Q]`6/^M3H%!)/L`35JBOB/
MQUOK?UULT_Q.[RZ'\_G_``2Q_P""4WP3L?V#/V:M*_;$_9RU+6_B_H-EXTO/
M&GPO^-7C'X@>-_`>F:P_Q*\=-H<UY\$/$7C;7?@O#<?\(Y=:9>VAMO!.U9+D
M:GQJ<\URW]`=%%>CF>:8S-L77Q6+K5)NMB<3B8495:M2CAGBJKJSI8>%6<_9
M4D^6$8I_!"";?*CCP.`PV7X>EA\/3C%4Z-&BZBA"-2JJ%-4X2JRA&//.UVW:
MR<I-)79^<O[3?[*_A+]I;]K_`/9GNOBI\.]3\:?"3P+^SQ^U_::IJ-OK?B;P
MYINB_$/QC\0_V)KCP'87>J^%-<T'4GO-<\->#?B;<6-D]S/82PZ'J$US$MS;
MV#'QOQ9^P#\+_@[^V%_P3Z^*/[._P>UC2+'P=\8OC?=?%GQ);^+O'?B>Q\/>
M$-;_`&1/CUX3T*\U:#Q?XLURULH+[QSXA\-Z);7=E:I=M?ZI;6[2"WFEK]?J
M*WHY[F%"C0P].M4CAJ&7X[+OJ\:U:-"I2QZQJJU*E)5.252/UZ?*[*+]G3YH
MNSOSU<GP56K6K2IQ]M6QN#QKK>SI^VA+`O!NE2C4<'/V;6"A&:;ORU*JBUS:
M%?BUX0^!/[=/QU_:P^+O[:-C\1/A_P#LW0>'XO$G[+W[-?P]^.GP`\=_&N^B
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MO`T?BWQ%\7;#28K>[O\`3=$M?U@O&"P.3P!M;H3]V1">`"3P#T!^AJU148_'
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M2KODA%^TJ17[R*:I<RYX4XU)UIU?SY_:$^!TOQC_`&Q?V?\`_A*?`LGB_P""
M%S^R3^W;\(/BV]Y;M+X;D@^,_B']D&VTSP;KC)-!*1XV\-^#?'L,4=NVXVFC
M:EF>WD$#2?(?[&G[+?[4T?QU\)V?[6-W<ZS\(/\`@F_X7\3_``<_8_\`$L_B
M'4K_`%3]H;6?'\.IZ;HW[2?CS3M,E\.6'_"7_"S]EJ^\'?L_Q6^N>&/%0O?B
M-XJ^/_BW3?%4E[=V_P!G_<*BG2SW&4<$\#3C0]FL)+"4JLH3E7P_M,1C:M:M
MAY^T4:=2O0S#%8&NE!TZN%FE.#K4J-6G$\IP\\5]:E4K.3Q*Q$H)P5.;C0PM
M*E3J1Y'SPH5,'0Q-&[3C6C*[E3J583^+_P#@G-X$\7_"[]@O]CSX;_$#0-0\
M*>.?`G[./PA\)^+_``UJJ)%J6@^(]"\$Z/INL:1?)&\L:W>GWUO/:SA)'021
MML=EP3XM_P`%,_`/[0G[27P^\'?L6_`FVU3P?HG[36J>(?#W[0/[05SH<^N>
M"_A%\!?#&@_V[XN\/ZE8Z3\0_A]XFU7Q/\;]1DT/X4:5X?T6]>'4O!>N?$:3
M4]8\)O;:7K:?IS16,<TK+-:F<.G0EB98C$8R$)0<J-+%593J4:RIRDU/ZK6E
M&M3IU>>E4G3C&O"I2<Z<M98"$\OAEKJU51CAZ.%E.#Y*M2A2C3IS@Y1LX^WI
M0E3J2I\DXQJ2=.4)J,U^%'[3/[(7_!0#PS9?`W]I#X<_%G]FSXI_$C]AO5+C
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M&\^-_P`-?'/[/>E^.=&\#_$?P!X2\6>)/">C^//AMJ_@OQ4="\;>!?#5_J'Q
M2M_$^FZ5XB\&:)XIMM1UG0K?Z"^'_P"V#X@^,/Q&\'^%/A=^RS^TH?`5Y=W/
M_"R_C)\:OAQKG[,_ACX>:<OA'Q9JVGP:5X)^.&G>$?C!\3/$VH^+-)\,>%OL
M7@[X=R^#=.L/$U[XCU+X@6KZ#!H6O?;%%55S"GB*=-XG!TJV*I82E@J>)]KB
M(<U'#T(X;#2K4HU+3K86A3I4\/*G*C2<:-/ZS1Q+YW-4\%.C.?L<55IT*F(J
M8F=#DHSM4K5'6K1IU)PE*-.O6E4J5E+VD^:K/V-2@N51*_E_^#?[-?@+P7\7
MOV]M4_:C_8%_:S^+.N?%#]OK]H#XJ_"WQO\`"[3?$<GA;5_@WXIC\(V_A6YB
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M&4+Q?XO_`!V^)WQ"_;R\0_LJ_"OX(?LZ_M#^"_#_`(#_`&LOV=/VB?CG\4/V
MBO@YXL^`7A+X?^"?@%XR3XJWW@_0K7XGQ^&/%7Q,^(WBOQ-X5\.^#M#_`.%6
M^&O'?@&SCUNYUOQ#XUT?2K:"\G_:"BBGB\9'$4\/AZ-".&PV%]LZ=-3E5G*I
M7E&56I5JSMS2?)"$5"%.G&E3@N1U/:5:AA\,Z-2M6J576KU_9J<^2-.,84HM
M4Z<(1O9)RG-RE*<Y3G+WE!0A#X>_X*'>`O&/Q+_9LC\)^`O#NI>*?$?_``T)
M^QGXI_L?28EFO3X>^'_[97P"\?>,]5$;.@:V\/>#_#6NZ_?[29!8:9<M$DDB
MK&_W#1164\3.>$H8-QC[/#XC%8F,E?G<\73PE.<9:\O+%8.FX62=YSNVN51T
MC0A'$U<2G+GK4:%"2=N51P\\1.+6E[R>(DI7;^&-K:GP!_P50^&WCKXP_P#!
M/#]KCX7_``R\,:GXS\?^-_@]KV@^%/"VC)'+JNN:O=3V1M]/L(I9(8Y+B78V
MQ6E0'!YK[_%%%$L3.6#H8)QC[.ABL7BHS5^=SQE'`T9QEKR\L8X&FX6BG><^
M9M<JB1H1CB:N)YI.56A0H..G+&.'GB:D9+2_-)XF2E=M6A#E2?,Y?F+^TU\%
M/BS\.?VQOA/_`,%"/@5\.;KXY:OX>^!GB_\`99^._P`%=.\2>&_#OCG7O@UX
MF^('A;XE>&_&?P1N?&VO^#O`,GQ#\#>-]&N[GQ#X=\;^+=(T_P`;>"M2NM,T
M+4=,\4Z9I*ZIZ%HO[<6N?$/7?"'A7X/?L@?M:>(]:U?Q#X5LO'>H?%?X2:]^
MS1X'^$OA>_\`%>C:3XR\1^(?&7QPM?"MMX_OO"OABZUWQ'I/AKX$V'Q;N?%U
M_H]EHT5]HVEZP_BK2_OBBNK^T*=2AAZ6*P=+$U,'1EA\/6=7$4FZ+G4J0IXB
M-.HO;*C.K-T94W0J)-0JSJTX4X1YU@I4ZU:IA\3.C#$U8UJ]/V=*I^\4(4W*
MC.<6Z;J1IQ]JIJM%N\J<:<Y2DROQ<\/_``,_;E^/7[8'Q;_;$T[QWX#_`&:=
M/^'\7B7]EK]F7P'\=/@%XU^-;W_P6T[4O#FN>/\`X^Z7H/A7]KGX0:%X/\0_
MM`?$K1S:/-K_`((M?'$GPJ^%OPJLYQIMI/?#6?VCHK/`YA5P"Q3H4Z$JF*H/
M#.I7H4L0J="<DZ\84J\*E%NO&*I3E.G)JE*I"-O:-FF*P=/&>Q56=94Z-55E
M3I59T>>K&+5.4ZE)PJVI.3J1C&<8NHH3DI.G&WY)_L9_";]J?]DS]J#XS_"/
MXF:CI7QA_9^_:0;Q1^U!X2^+'P\\#^*?A]X'^$?[1.N>)Y?^%W_!X_#_`,6?
M&'X]^(?#'AWXJ?VCIWQT\/:HOC+0_`T7Q`O_`(KZ3H6A6EWK]EI]O^LMR<6\
MQ_Z9M[]O8?TJ>BIQ^.JYCB%BJ\*,:[I4(5I4::I0KU*$536(G2@U3A5J0C35
M7V4:<)SBZO(IU)N3PF$A@Z+P].=25%5*DJ4:DG-TH5'SNC&<FYRIPFYNGSRE
M*$)*FI.$(I?A[_P3W^/OQ$_9E_8F_9E^`'Q(_8H_;6/CWX4_"WPWX+\4MH/P
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M[U154X0I4J,9^VG";GB/91C]8K4N14\/5DHRIT)3A+VDYSJ,HHHKR3T`HHHH
M`****`"OPO\`^"\?[,7C?]LGX.?L6?LV?#Z:TLO$7Q-_;Z\"6<NK7S6QM/#O
MAG0OV<OVH/%'C7Q1-;W-_IBZB/#/@_1-;UR+1X;^VO-<N+&'1=/E_M#4+1'_
M`'0JI<6%E=S6-S<VEM<7&FW$EWIT\\$<LMC=2VES82W-G(ZEK:XDL;R\LGFA
M*2-:7=S;EC#/*C>GDV:5LES/"9IAU%XC!SG5H<ZO!5G2G"G.4;/FC"<E.4/M
MJ+C=7NN+,<#3S+!UL%6<E1Q'LXU7%VE[-583FHOHY1BXJ5FXWNDVK'Y;?LK?
M\$<?V)?V8/#VBVQ^'J_&CQK9Z5<Z?K/CCXPRR>*H-:DOYH+F\DC^'<TH^&>E
MPVTD"6FARP>%9_$&G:2OV.]\1ZO=76J:CJ/Z:^%_"OAGP3H6F^%_!WAW0_"G
MAK1K6.QT?P]X;TFQT/0])LH1B*STS2=-@MK"PM(LL8[>U@BA0LQ5`6)._166
M.S/,<SJRK9ACL5C*LI.3E7K3J)-[\L')P@NT8145HDE9&]##T,-"-.A2A2A!
M*,8Q6R226NK>BW;;>[U"BBBN$V"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
0*`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
